论文部分内容阅读
目的：探讨肝动脉化疗栓塞治疗老年人原发性肝癌的疗效及其影响生存的因素。材料和方法：５６例有完整资料的老年人原发性肝癌分别经肝动脉化疗和栓塞术（ＨＡＩ和ＨＡＥ）后，观察肿瘤缩小程度和生化指标，并随访其生存时间和生存率。结果：５６例平均生存期为１４７月，其中ＨＡＩ为９７月，ＨＡＥ为１６３月，一年生存率ＨＡＥ组明显高于ＨＡＩ组，分别为６２８％和２３１％（Ｐ＜００５）；巨块型、结节型和弥漫型三组一年生存率分别为５９５％、６６７％、０％；临床分期、门脉癌栓和功能状态对生存率影响差异无显著意义：一次和多次ＨＡＥ比较对肿瘤缩小程度差异无显著性；所有病例术后均无严重并发症。结论：ＨＡＥ是老年人原发性肝癌安全有效的治疗方式和影响生存率的主要因素，首次ＨＡＥ尤为重要
Objective: To investigate the efficacy of hepatic arterial chemoembolization in the treatment of primary liver cancer in the elderly and the factors that influence survival. Materials and Methods: 56 cases of primary liver cancer patients with complete data were treated with hepatic artery chemotherapy and embolization (HAI and HAE) respectively. The degree of tumor shrinkage and biochemical parameters were observed. The survival time and survival rate were followed up. Results: The average survival time of 56 patients was 14 months and 7 months, of which HAI was 9 months and 7 months, and HAE was 16 months and 3 months. The one-year survival rate in the HAE group was significantly higher than that in the HAI group, which was 62.8% and 23%, respectively. % (P<005); The one-year survival rates of the massive, nodular and diffuse groups were 59.5%, 66.7%, and 0%, respectively; clinical staging, portal vein cancer emboli, and functional status. There was no significant difference in the impact on survival rate: One or more HAE comparisons had no significant difference in tumor shrinkage; all patients had no serious postoperative complications. CONCLUSIONS: HAE is a safe and effective treatment for primary liver cancer in the elderly and is a major factor affecting survival. The first HAE is particularly important.